Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

作者信息

Lu Jonathan E, Chang Jessica R, Berry Jesse L, In Gino K, Zhang-Nunes Sandy

出版信息

Int Ophthalmol Clin. 2020 Spring;60(2):77-89. doi: 10.1097/IIO.0000000000000308.

DOI:10.1097/IIO.0000000000000308

PMID:32205655

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8059069/

Abstract

摘要

相似文献

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Int Ophthalmol Clin. 2020 Spring;60(2):77-89. doi: 10.1097/IIO.0000000000000308.

[Palpebral and conjunctival tumors treated by hematoporphyrin-laser therapy].

Zhonghua Yan Ke Za Zhi. 1987 Jul;23(4):206-8.

Efficacy of immune checkpoint inhibitors in different types of melanoma.

Hum Vaccin Immunother. 2021 Jan 2;17(1):4-13. doi: 10.1080/21645515.2020.1771986. Epub 2020 Jul 14.

Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit.

Int Ophthalmol Clin. 2019 Spring;59(2):13-26. doi: 10.1097/IIO.0000000000000271.

Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Ophthalmic Plast Reconstr Surg. 2021;37(1):e9-e13. doi: 10.1097/IOP.0000000000001700.

Successful Treatment of Extensive Squamous Cell Carcinoma of the Conjunctiva and Upper Eyelid Skin With Topical Therapy Alone.

Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S4-S6. doi: 10.1097/IOP.0000000000000601.

Azelaic acid in the treatment of ocular and adnexal malignant melanoma.

Br J Ophthalmol. 1983 Jan;67(1):54-7. doi: 10.1136/bjo.67.1.54.

[Analysis of changes in the accumulation of the photosensitizer Photosens, its elimination kinetics and distribution in the tissues of the eye and eyelids in health and in some tumorous processes].

Vestn Oftalmol. 2008 Jan-Feb;124(1):38-44.

Pigmentation of the eyelid margin accompanying conjunctival melanoma.

Am J Ophthalmol. 1989 Oct 15;108(4):435-9. doi: 10.1016/s0002-9394(14)73313-6.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263.

引用本文的文献

Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.

Pathol Oncol Res. 2025 Aug 4;31:1612085. doi: 10.3389/pore.2025.1612085. eCollection 2025.

Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.

Ophthalmic Plast Reconstr Surg. 2023;39(5):e152-e155. doi: 10.1097/IOP.0000000000002407. Epub 2023 May 16.

Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.

Int J Pharm. 2023 Jun 10;640:123043. doi: 10.1016/j.ijpharm.2023.123043. Epub 2023 May 11.

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

J Ophthalmic Vis Res. 2022 Aug 15;17(3):405-412. doi: 10.18502/jovr.v17i3.11579. eCollection 2022 Jul-Sep.

本文引用的文献

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

JAMA Oncol. 2019 Sep 1;5(9):1332-1339. doi: 10.1001/jamaoncol.2019.2244.

Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.

J Immunother Cancer. 2019 Mar 25;7(1):83. doi: 10.1186/s40425-019-0555-7.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263.

Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma.

Ocul Oncol Pathol. 2018 Jun;4(4):261-266. doi: 10.1159/000485978. Epub 2018 Feb 1.

Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma.

Cancer Immunol Immunother. 2019 Jan;68(1):85-95. doi: 10.1007/s00262-018-2260-7. Epub 2018 Oct 11.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Int Ophthalmol Clin. 2020 Spring;60(2):77-89. doi: 10.1097/IIO.0000000000000308.

Efficacy of immune checkpoint inhibitors in different types of melanoma.

Hum Vaccin Immunother. 2021 Jan 2;17(1):4-13. doi: 10.1080/21645515.2020.1771986. Epub 2020 Jul 14.

Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Ophthalmic Plast Reconstr Surg. 2021;37(1):e9-e13. doi: 10.1097/IOP.0000000000001700.

Successful Treatment of Extensive Squamous Cell Carcinoma of the Conjunctiva and Upper Eyelid Skin With Topical Therapy Alone.

Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S4-S6. doi: 10.1097/IOP.0000000000000601.

Azelaic acid in the treatment of ocular and adnexal malignant melanoma.

Br J Ophthalmol. 1983 Jan;67(1):54-7. doi: 10.1136/bjo.67.1.54.

Pigmentation of the eyelid margin accompanying conjunctival melanoma.

Am J Ophthalmol. 1989 Oct 15;108(4):435-9. doi: 10.1016/s0002-9394(14)73313-6.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263.

Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.

Pathol Oncol Res. 2025 Aug 4;31:1612085. doi: 10.3389/pore.2025.1612085. eCollection 2025.

Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.

Ophthalmic Plast Reconstr Surg. 2023;39(5):e152-e155. doi: 10.1097/IOP.0000000000002407. Epub 2023 May 16.

Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.

Int J Pharm. 2023 Jun 10;640:123043. doi: 10.1016/j.ijpharm.2023.123043. Epub 2023 May 11.

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

J Ophthalmic Vis Res. 2022 Aug 15;17(3):405-412. doi: 10.18502/jovr.v17i3.11579. eCollection 2022 Jul-Sep.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

JAMA Oncol. 2019 Sep 1;5(9):1332-1339. doi: 10.1001/jamaoncol.2019.2244.

Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.

J Immunother Cancer. 2019 Mar 25;7(1):83. doi: 10.1186/s40425-019-0555-7.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263.

Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma.

Ocul Oncol Pathol. 2018 Jun;4(4):261-266. doi: 10.1159/000485978. Epub 2018 Feb 1.

Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma.

Cancer Immunol Immunother. 2019 Jan;68(1):85-95. doi: 10.1007/s00262-018-2260-7. Epub 2018 Oct 11.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.

Suppr
超能文献

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr超能文献

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr
超能文献